Dose‐finding results in an adaptive, seamless, randomized trial of once‐weekly dulaglutide combined with metformin in type 2 diabetes patients (<scp>AWARD</scp>‐5)
Zachary Skrivanek(Eli Lilly (United States)), Donald A. Berry(Berry & Associates (United States)), Zvonko Miličević(Eli Lilly (United States)), Brenda Gaydos(Eli Lilly (United States)), Thomas Först(University College London), Jenny Y. Chien(Eli Lilly (United States)), Margarethe Geiger(Regeneron (United States)), Michael Heathman(Eli Lilly (United States)), James H. Anderson(University of North Carolina at Chapel Hill), Scott Berry(Queen's University)
Cited by 72
Related Papers
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis
|JAMA|2019|1.5k
Revision of the American Joint Committee on Cancer Staging System for Breast Cancer
|Journal of Clinical Oncology|2002|1.2k
Comparison of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation
|JAMA|2010|1.2k
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
|New England Journal of Medicine|2013|980
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
|Alzheimer s Research & Therapy|2021|818